PDCD1 and melanoma: Some studies have shown that high pre-treatment plasma levels of IFNγ, Interleukin 6 (IL6), and IL10 [12] and Transforming Growth Factor β (TGF-β) [13] are associated with response to anti-PD-1 therapy in melanoma patients.